Press releases
Access archived Guidant press releases
Access archived BTG press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
May 20, 2015Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and SafetyA new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic...
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One YearBoston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
May 12, 2015Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public...
May 11, 2015Boston Scientific (NYSE: BSX) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16....
- May 7, 2015
Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration...
May 6, 2015Recognition From Shingo Institute is the Second in Two Years for a Company FacilityBOSTON SCIENTIFIC Coyol, COSTA RICA FACILITY EARNS SHINGO AWARD FOR EXCELLENCE IN OPERATIONS Recognition From Shingo Institute is the Second in Two Years for a Company Facility COYOL, Costa Rica...
May 1, 2015Boston Scientific Corporation (NYSE: BSX) is presenting an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community today in New York...
- Apr 30, 2015Customized Programs to Drive Operational and Care Pathway Improvements
Boston Scientific (NYSE: BSX) announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of...
Apr 28, 2015Boston Scientific Corporation (NYSE: BSX) generated sales of $1.768 billion during the first quarter ended March 31, 2015, compared to the company's guidance range for the quarter of $1.740 to...
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling ResultsIn an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
Apr 27, 2015Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2015 Healthcare Conference on May 12 in Las Vegas. Dan Brennan, executive vice president...
Apr 27, 2015Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
- Apr 24, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 40th Annual Healthcare Conference on May 6 in Boston. Dan Brennan, executive vice president and chief...
Apr 20, 2015Results Published in the Journal of American College of CardiologyToday the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX) S-ICD System™ (subcutaneous...
Apr 16, 2015Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the...
- Apr 14, 2015Companies Plan to Accelerate Physician Training and Expand Utilization of Less-Invasive Endoscopy Technologies in China
Boston Scientific Corporation (NYSE: BSX), a leading global medical device company, announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader...
- Apr 1, 2015
Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and...
- Apr 1, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast a conference call on Tuesday, April 28, 2015 at 8 a.m. ET to review financial results and business highlights for the first quarter 2015. The...
Mar 24, 2015Novel Stroke Risk Reduction Option for Indicated Patients with Atrial FibrillationThis week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device. The WATCHMAN...
Mar 17, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrestBoston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
- Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
Mar 3, 2015Boston Scientific Corporation (NYSE: BSX) announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the...
Mar 2, 2015Combined Business to Advance Patient Care with Leading Solutions Across Major Urology CategoriesBoston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to acquire the American Medical...
- Feb 27, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays 2015 Annual Healthcare Conference on March 10 in Miami Beach. Dan Brennan, executive vice president and chief...
Feb 26, 2015Boston Scientific Corporation (NYSE: BSX) announces 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for cholangioscopy and pancreatoscopy procedures. Built...
- Feb 25, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen 35th Annual Healthcare Conference on March 4 in Boston. Dan Brennan, executive vice president and chief financial...
- Feb 17, 2015
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation, stemming from Boston...
- Feb 13, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the RBC Capital Markets 2015 Global Healthcare Conference on February 25 in New York City. Dan Brennan, executive vice...
- Feb 9, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink 2015 Global Healthcare Conference on February 11 in New York City. Susan Lisa, vice president, Investor...
Feb 9, 2015Agreement Extends Reach of Lutonix DCB and Provides Physicians with a Comprehensive Solution to Prepare and Treat Diseased Femoropopliteal VesselsBoston Scientific Corporation (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) ("Bard") today announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous...
- Feb 4, 2015
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.887 billion during the fourth quarter ended December 31, 2014, compared to the company's guidance range for the quarter of $1.875 to...
Feb 3, 2015IndustryWeek recognition highlights manufacturing excellenceThe Boston Scientific (NYSE: BSX) Maple Grove Operations facility, Maple Grove, Minn., has been named a 2014 Best Plants winner by IndustryWeek magazine. IndustryWeek annually recognizes...
Feb 2, 2015Boston Scientific Corporation (NYSE: BSX) announces the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including DYNAGEN™ EL...
Jan 20, 2015Marlborough, Mass. (January 20, 2015) – Boston Scientific Corporation (NYSE: BSX), a global medical device company headquartered in Marlborough, Massachusetts, will co-sponsor the 2015...
Jan 15, 2015Boston Scientific Corporation (NYSE: BSX) will host and webcast an Investor Day business review meeting for the investment community on Friday, May 1, 2015. The meeting and webcast are scheduled...
- Jan 7, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2014 on...
-
Dec 22, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 in San Francisco. Mike Mahoney, president...
-
Dec 18, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January 6, 2015 in Boston. Mike Mahoney, president and...
-
Dec 12, 2014Significant Relief Achieved Using Advanced Illumina™ 3D Programming Software
New retrospective data evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly...
-
Nov 19, 2014
Boston Scientific has scored the highest rating of 100 percent in the Human Rights Campaign (HRC) Foundation's 2015 Corporate Equality Index (CEI). The top mark distinguishes the company as one of...
-
Nov 19, 2014EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent...
-
Nov 17, 2014
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids...
-
Nov 13, 2014New CPT Category I Code Facilitates Processing for U.S. Hospitals and Physicians
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current Procedural Terminology (CPT®) Category I codes...
-
Nov 5, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president...
-
Nov 4, 2014Event will be held in Chicago, Site of the 2014 American Heart Association Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and...
-
Nov 3, 2014Data Will Focus on Long-Term Back Pain Relief Using the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System and Highlight Research on Stimulation Waveforms
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical...
-
Oct 30, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 in Phoenix, AZ. Dan Brennan, executive...
-
Oct 22, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.846 billion during the third quarter ended September 30, 2014, compared to the company's guidance range for the quarter of $1.790 to...
-
Oct 21, 2014World's First 32-contact SCS Surgical Leads Designed to Provide More Focused Pain Relief for Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge™ 32 and CoverEdge™ X 32 Surgical Leads, the world's first...
-
Oct 20, 2014First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 8, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2014 on Wednesday, October...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 15, 2014No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year
New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus™ Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe...
-
Sep 10, 2014Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in...
-
Sep 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England. Michael...
-
Sep 2, 2014
Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 25, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY. Mike Mahoney, chief executive officer, and
-
Aug 19, 2014Companies Reach Agreement to Develop a New and Differentiated FFR Guidewire and Next Generation Boston Scientific Rotablator™ RotaWire™
Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional...
-
Jul 24, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to...
-
Jul 23, 2014Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market...
-
Jul 22, 2014Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products
Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular...
-
Jul 21, 2014Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of...
-
Jul 14, 2014European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely
Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System,...
-
Jul 14, 2014Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease
Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger™...
-
Jul 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday,...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan Brennan, executive vice president and chief...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in Rancho Palos Verdes, CA. David Pierce, senior vice...
-
May 21, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 15, 2014Boston Scientific Offers World Class Endoscopy Training at its Paris Institute for Advancing ScienceBoston Scientific Reinforces Its Commitment to Global Education and Innovation
Boston Scientific Corporation (NYSE: BSX) celebrated the opening of a new facility dedicated to endoscopy training within its Institute for Advancing Science in Paris. The ceremony included major...
-
May 15, 2014Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire the...
-
May 10, 2014PREDICt-RM Collaborative Study between Boston Scientific, American College of Cardiology and Yale University Highlights Improved Outcomes in ICD and CRT-D Patients followed with the LATITUDE™ System
Patients using the Boston Scientific Corporation (NYSE: BSX) LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer...
-
May 8, 2014Boston Scientific Shockless Implant Evaluation (SIMPLE) Study Results Presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions
A Boston Scientific Corporation (NYSE: BSX) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine...
-
May 8, 2014Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...
-
May 6, 2014Innovative Technology Designed to Treat Intrauterine Fibroids and Polyps
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has...
-
May 6, 2014Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions
Boston Scientific Corporation (NYSE: BSX) has joined Optum Labs as the Founding Medical Device Partner to help pioneer new research into effective treatments for heart failure and related cardiac...
-
May 5, 2014Broad Set of Data Reinforces Commitment to Advancing Research and Technology in Electrophysiology
Boston Scientific Corporation (NYSE: BSX) will be presenting new data at the 35th Annual Scientific Sessions of the Heart Rhythm Society in San Francisco on May 7-10, highlighting the company's...
-
May 1, 2014Promising Clinical Data to be Presented at Annual Conference
Boston Scientific Corporation (NYSE: BSX) will present select abstracts and clinical data analyses pertaining to key issues in gastroenterology during Digestive Disease Week (DDW®) 2014, May 4-6...
-
May 1, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2014 Healthcare Conference on May 13 in Las Vegas, NV. Susie Lisa, vice president,...
-
May 1, 2014
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Apr 29, 2014Company Exceeds Earnings Per Share Guidance on the Strength of Continued Revenue Growth
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent operational revenue growth (constant currency...
-
Apr 22, 2014
Boston Scientific Corporation (NYSE: BSX) has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ 4-FRONT...
-
Apr 17, 2014Event Will Be Held in San Francisco, Site of the Heart Rhythm Society 35th Annual Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and Electrophysiology initiatives as well as...
-
Apr 15, 2014
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved...
-
Apr 10, 2014Study to Evaluate Clinical Outcomes and Economic Value of the Vercise™ Deep Brain Stimulation (DBS) System
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS)...
-
Apr 7, 2014The first implant of the S-ICD System performed in Hong Kong
Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat...
-
Apr 7, 2014Innovative handle design enables physician preferences for precision, comfort and control when acquiring tissue samples during diagnostic procedures
Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...
-
Apr 1, 2014These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease
Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...
-
Apr 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...
-
Apr 1, 2014Interim results of the EFFORTLESS registry published in the European Heart Journal
Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE:...
-
Mar 27, 2014Includes Late Breaking Clinical Trial Assessing Use of the Boston Scientific CRT-D Therapyin Patients with Mild Heart Failure
At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation...
-
Mar 19, 2014
Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University, in...